Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
Rain Therapeutics Presents Data On Milademetan (RAIN-32) At 2021 AACR-NCI-EORTC Virtual International Conference
Rain Therapeutics Inc., (NASDAQ:RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced data on its oral mouse double minute 2 (MDM2) inhibitor, milademetan, presented
Rain Therapeutics To Present On Milademetan At 2021 AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics
NEWARK, Calif., October 1, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NASDAQ:RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced it will be presenting three
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
48 Biggest Movers From Yesterday
Gainers
Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients.
The Past Week’s Notable Insider Buys: Continental Resources, Oscar Health And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.
The week's most notable insider buys were at a health insurer, an oil exploration and production company, and a biotech.
Some insiders were making return trips to the buy window.
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues, clinical readouts and regulatory actions that moved stocks during the week.
Rain Therapeutics Q2 EPS $(0.39) Beats $(0.60) Estimate
Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.60) by 35 percent.
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.